SecBot SecBot
6-K ·Filed Jul 1, 2026

EVAX

Evaxion A/S
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago SEC0001171843-26-004414
Notable filing: 6-K
Actionable Insight • Neutral

Monitor the poster presentation on July 12 for any data readouts on immune response or viral neutralization. No immediate trading catalyst; the stock may see limited movement unless the data reveals a clear differentiation from existing CMV vaccine approaches.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.20
T+0 close · Jul 1, 2026 · via day close
Latest settled
+1.88%
T+60 · $3.26
Vs SPY
−1.08%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 1 $3.20entry
  2. T+1 · 5mo ago +6.56%α +6.69% · $3.41
  3. T+5 · 4mo ago +3.44%α +3.18% · $3.31
  4. T+20 · 4mo ago −11.25%α −9.06% · $2.84
  5. T+60 · 8w ago +1.88%α −1.08% · $3.26
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion announced a poster presentation of preclinical data for its CMV vaccine candidate EVX-V1 at the International Herpesvirus Workshop on July 12, 2026. The data will guide final antigen selection for the candidate, which combines AI-discovered and AI-optimized antigens. This is a routine pipeline update with no financial or clinical data disclosed.

Key Facts

  • Evaxion will present preclinical data for CMV vaccine candidate EVX-V1 at IHW 2026 in Montreal on July 12, 2026.
  • EVX-V1 is a multi-component vaccine combining novel AI-discovered antigens with AI-optimized versions of established CMV antigens.
  • No CMV vaccine has been approved to date; the CMV treatment market was valued at $474.6M in 2023 with 6.6% CAGR forecast.
  • The presentation will guide final antigen selection for a broadly protective CMV vaccine candidate.

Financial Impact

No financial figures disclosed; preclinical data presentation has no direct revenue or earnings impact.

Risk Factors

  • Preclinical data may not translate to clinical efficacy or regulatory success.
  • Evaxion is a clinical-stage company with no approved products and likely needs additional capital to fund development.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-004414
Document: f6k_070126.htm0001171843-26-004414
Document: 0001171843-26-004414-index-headers.html0001171843-26-004414
Document: 0001171843-26-004414-index.html0001171843-26-004414
Document: 0001171843-26-004414.txt0001171843-26-004414

Track record

50 reports on EVAX

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026